Given that SHIP1 acts as a negative regulator of the TREM2 pathway, we expect that the benefits of INPP5D downregulation on AD progression may directly correspond to the extent that TREM2 upregulation ameliorates disease progression. The gene discussed is INPP5D; the disease is Alzheimer disease.